#ASH22: Kura’s menin inhibitor heads to PhII in subset of acute myeloid leukemia with mixed data
NEW ORLEANS — Kura Oncology said the FDA has agreed on a Phase II dose for a registrational trial of its lead drug, and at a major hematology medical conference Saturday morning, the biotech disclosed new Phase Ib expansion cohort data as it builds toward a competition with Syndax Pharmaceuticals.
In back-to-back sessions Saturday morning at the annual American Society of Hematology congress, Kura and Syndax gave updates to Phase I studies testing their rival menin inhibitors — both vying to treat patient subsets of acute myeloid leukemia that don’t yet have mutation-specific medicines: NPM1 and KMT2D, also known as mixed lineage leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
